Discovery of a novel inhibitor of macropinocytosis with antiviral activity
B. Porebski, W. Christ, A. Corman, M. Haraldsson, M. Barz, L. Lidemalm, M. Haggblad, J. Illmain, S. Wright, M. Murga, J. Schlegel, E. Sezgin, G. Bhabha, V. M. Lauschke, M. Lafarga, J. Klingstrom, D. Huhn, O. Fernandez-Capetillo
Abstract
Several viruses hijack various forms of endocytosis in order to infect host cells. Here, we report the discovery of a new molecule with antiviral properties that we named virapinib, which limits viral entry by macropinocytosis. The identification of virapinib derives from a chemical screen using High-Throughput Microscopy, where we identified new chemical entities capable of preventing infection with a pseudotype virus expressing the spike (S) protein from SARS-CoV-2. Subsequent experiments confirmed the capacity of virapinib to inhibit infection by SARS-CoV-2, as well as by additional viruses, such as Monkeypox virus and TBEV. Mechanistic analyses revealed that the compound inhibited macropinocytosis, limiting this entry route for the viruses. Importantly, virapinib has no significant toxicity to host cells. In summary, we present a new molecule that inhibits viral entry via the endocytic route, offering a new alternative to prevent viral infection.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dual inhibition of vacuolar ATPase and TMPRSS2 is required for complete blockade of SARS-CoV-2 entry into cells
- Post-Infection Entry Mechanism of Ricin A Chain-Pokeweed Antiviral Proteins (RTA-PAPs) Chimeras is Mediated by Viroporins
Yasser Hassan·bioRxiv·Jun 17, 2021
- Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2
Y.-L. Kang, Y.-Y. Chou, … T. Kirchhausen·bioRxiv·Apr 21, 2020
- Green tea and Spirulina extracts inhibit SARS, MERS, and SARS-2 spike pseudotyped virus entry in vitro
J. Joseph, K. Thankamani, … V. S. Raj·Current Pharmaceutical BiotechnologyPeer-reviewed·Jul 1, 2022
- Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S and MERS-S pseudotyped particles
C. Z. Chen, M. Xu, … G. R. Whittaker·bioRxiv·Jul 10, 2020
- A syntenin inhibitor blocks endosomal entry of SARS-CoV-2 and a panel of RNA viruses
R. Lindqvist, C. Benz, … A. K. Overby·bioRxiv·Aug 18, 2022